ArriVent BioPharma, Inc. Common Stock
ArriVent BioPharma, Inc. Common Stock (AVBP) Revenue
Annual & quarterly revenue history · segment & region breakdown
AVBP · revenue · updated Jun 8, 2026
Core revenue metrics
Trailing 12 monthsArriVent BioPharma, Inc. Common Stock trailing twelve-month (TTM) revenue is $0.00B, an increase of 0.00% year-over-year from $0.00B in FY2025.
Revenue trend
2025 – 2021 · AnnualRevenue history
| Fiscal year end | Revenue | Change | Growth |
|---|---|---|---|
| 2025-12-31 | $0.00B | +$0.00B | — |
| 2024-12-31 | $0.00B | +$0.00B | — |
| 2023-12-31 | $0.00B | +$0.00B | — |
| 2022-12-31 | $0.00B | +$0.00B | — |
| 2021-12-31 | $0.00B | — | — |
Compare revenue vs peers
BiotechnologyCompare AVBP revenue against listed peers. Click any row to open that company's revenue tab.
About Revenue & Reporting
Revenue (also called sales, net sales, or turnover) is the total income ArriVent BioPharma, Inc. Common Stock receives from its business operations before deducting any costs or expenses. It is the top line of the income statement. Unlike net income or earnings, revenue does not account for operating costs, taxes, interest, or depreciation.
ArriVent BioPharma, Inc. Common Stock reports revenue on a fiscal year ending Dec 31 basis under US GAAP, denominated in USD.
Data sourced from ArriVent BioPharma, Inc. Common Stock's 10-K and 10-Q SEC filings via Financial Modeling Prep.
Frequently asked questions
AVBP revenue · 4 questionsAVBP's trailing twelve-month (TTM) revenue is $0.00B. That is an increase of 0.00% year-over-year from $0.00B in FY2025.
▸ Source: FMP · ArriVent BioPharma, Inc. Common Stock SEC filings · GAAP · ArriVent BioPharma, Inc. Common Stock SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026